Key result
Angiogenic growth factor therapy fails to demonstrate clinical efficacy in late-stage myocardial ischemia trials.
Answers are grounded in this paper and cite their sources.
Review identifies obstacles impeding angiogenic gene therapy for myocardial ischemia, suggesting strategies to optimize future clinical trials.
Well-developed coronary collateral vessels in patients with symptomatic coronary artery disease were shown to be associated with reduced future cardiovascular morbidity and mortality. However, the majority of patients with coronary artery disease lack adequate functional coronary collateral circulation. Stimulation of collateral vessel development by angiogenic growth factor therapy (therapeutic angiogenesis) has been tested in many clinical trials in the past, but the potential of this new treatment paradigm has not been realized yet in late stage clinical trials. Mechanistic insights into collateral vessel development and the collective clinical experience in the past decade identified specific obstacles that might have impeded the progress in the field. This review identifies some of the key conceptual, technical, and clinical hurdles and recommends strategies to overcome them in future clinical trials.
No takes yet. Share an insight, caveat, or question.
Gabor M. Rubanyi (2014) conducted a review in Myocardial ischemia / symptomatic coronary artery disease. Angiogenic gene / growth factor therapy (therapeutic angiogenesis) was evaluated. Angiogenic growth factor therapy for myocardial ischemia has not yet realized its potential in late-stage clinical trials due to conceptual, technical, and clinical hurdles.
Synapse has enriched 10 related papers. Consider them for comparative context: